Drug Combo Proves Powerful Against Lung Cancer Dunkirk NY

A two-drug combination treatment in Dunkirk proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Raman Sood
(716) 366-1223
617 Central Ave
Dunkirk, NY
RAMAN SOOD, MD
(716) 366-1223
617 Central Avenue
Dunkirk, NY
Vilasini M Shanbhag, MD
716-634-6503
529 Central Ave
Dunkirk, NY
Cr Wood Cancer Center At Glens Falls Hospital
(518) 926-6620
102 Park St
Glens Falls, NY
Feldman Eric MD
(914) 681-0025
311 North St
White Plains, NY
Robert Roche
(276) 228-7665
590 W Ridge Rd Ste L
Dunkirk, NY
Kaushik Damania
(716) 532-3377
100 Memorial Dr
Gowanda, NY
Ganesh N Deshpande, MD
716-672-7272
50 Brigham Rd
Fredonia, NY
Ahmed Tausee MD
(914) 681-0025
311 North St
White Plains, NY
Staten Island University Hospital
(718) 226-6400
256 Mason Ave
Staten Island, NY
Data Provided by:
  

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Hormone Therapy for Lung Cancer Dunkirk NY
Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.
- Side Effect Of Chemotherapy Drugs Dunkirk NY
- Fungal Infection Treatments Dunkirk NY
- Exercise for Breast Cancer Survival Dunkirk NY
- Hormone Therapy for Breast Cancer Dunkirk NY
- Exercise for Prostate Cancer Dunkirk NY
- Risks for Childhood Cancer Survivors Dunkirk NY
- Genetic Clues for Skin Cancer Therapies Dunkirk NY
- Delayed Prostate Cancer Therapy Dunkirk NY